Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.verified

TALS

Price:

$2.72

Market Cap:

$116.44M

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immu...[Read more]

Industry

Biotechnology

IPO Date

2021-05-07

Stock Exchange

NASDAQ

Ticker

TALS

The ROE as of November 2024 (TTM) for Talaris Therapeutics, Inc. (TALS) is -14.93%

According to Talaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -14.93%. This represents a change of 65.51% compared to the average of -9.02% of the last 4 quarters.

Talaris Therapeutics, Inc. (TALS) Historical ROE (quarterly & annually)

How has TALS ROE performed in the past?

The mean historical ROE of Talaris Therapeutics, Inc. over the last ten years is 7.87%. The current -14.93% ROE has changed -289.70% with respect to the historical average. Over the past ten years (40 quarters), TALS's ROE was at its highest in in the March 2021 quarter at 20.01%. The ROE was at its lowest in in the March 2023 quarter at -12.93%.

Quarterly (TTM)
Annual

Average

7.87%

Median

-17.60%

Minimum

-38.17%

Maximum

104.85%

Talaris Therapeutics, Inc. (TALS) ROE by Quarter and Year

Discovering the peaks and valleys of Talaris Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 92.45%

Maximum Annual ROE = 104.85%

Minimum Annual Increase = -114.65%

Minimum Annual ROE = -38.17%

Quarterly (TTM)
Annual
YearROEChange
2022-38.17%92.45%
2021-19.83%29.15%
2020-15.36%-114.65%

Talaris Therapeutics, Inc. (TALS) Average ROE

How has TALS ROE performed in the past?

The current ROE of Talaris Therapeutics, Inc. (TALS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-24.45%

5-year avg

7.87%

10-year avg

7.87%

Talaris Therapeutics, Inc. (TALS) ROE vs. Peers

How is TALS’s ROE compared to its peers?

Talaris Therapeutics, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Adicet Bio, Inc. (-53.85%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Vor Biopharma Inc. (-101.14%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Instil Bio, Inc. (-37.44%), greater than Neoleukin Therapeutics, Inc. (-8.54%), less than Spero Therapeutics, Inc. (3.36%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Nuvation Bio Inc. (-108.68%), greater than Achilles Therapeutics plc (-54.57%), greater than NextCure, Inc. (-62.50%), greater than Ovid Therapeutics Inc. (-39.24%), less than Connect Biopharma Holdings Limited (7.21%),

Build a custom stock screener for Talaris Therapeutics, Inc. (TALS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Talaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Talaris Therapeutics, Inc. (TALS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Talaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Talaris Therapeutics, Inc.'s ROE?

How is the ROE calculated for Talaris Therapeutics, Inc. (TALS)?

What is the highest ROE for Talaris Therapeutics, Inc. (TALS)?

What is the 3-year average ROE for Talaris Therapeutics, Inc. (TALS)?

What is the 5-year average ROE for Talaris Therapeutics, Inc. (TALS)?

How does the current ROE for Talaris Therapeutics, Inc. (TALS) compare to its historical average?